S&P 500
(0.30%) 5 115.21 points
Dow Jones
(0.25%) 38 334 points
Nasdaq
(0.34%) 15 981 points
Oil
(-0.94%) $83.06
Gas
(5.51%) $2.03
Gold
(0.29%) $2 353.90
Silver
(0.68%) $27.72
Platinum
(3.95%) $958.50
USD/EUR
(-0.24%) $0.932
USD/NOK
(-0.35%) $10.99
USD/GBP
(-0.58%) $0.796
USD/RUB
(1.67%) $93.41

リアルタイムの更新: Qiagen NV [QIA.DE]

取引所: XETRA セクター: Life Sciences Tools & Services 産業: Diagnostics & Research
最終更新日時30 4月 2024 @ 00:40

0.99% 39.15

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 00:40):

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories...

Stats
本日の出来高 753 805
平均出来高 661 659
時価総額 8.67B
EPS €0.500 ( 2023-10-30 )
Last Dividend €1.080 ( 2017-01-25 )
Next Dividend €0 ( N/A )
P/E 27.57
ATR14 €0.0170 (0.04%)

ボリューム 相関

長: -0.26 (neutral)
短: 0.53 (weak)
Signal:(41.171) Neutral

Qiagen NV 相関

10 最も正の相関
10 最も負の相関

知っていましたか?

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Qiagen NV 相関 - 通貨/商品

The country flag 0.04
( neutral )
The country flag -0.02
( neutral )
The country flag 0.00
( neutral )
The country flag 0.00
( neutral )
The country flag 0.46
( neutral )
The country flag 0.34
( neutral )

Qiagen NV 財務諸表

Annual 2023
収益: €1.97B
総利益: €1.23B (62.77 %)
EPS: €1.540
FY 2023
収益: €1.97B
総利益: €1.23B (62.77 %)
EPS: €1.540
FY 2022
収益: €2.14B
総利益: €1.38B (64.65 %)
EPS: €1.860
FY 2021
収益: €2.25B
総利益: €1.45B (64.43 %)
EPS: €2.26

Financial Reports:

No articles found.

Qiagen NV Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Qiagen NV Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 3.99 - Decrease likely (20.28%)
Information
First Dividend €1.080 2017-01-25
Last Dividend €1.080 2017-01-25
Next Dividend €0 N/A
Payout Date 2017-01-31
Next Payout Date N/A
# dividends 1 --
Total Paid Out €1.080 --
Avg. Dividend % Per Year 0.00% --
Score 2.13 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 3.99
Div. Directional Score 7.07 --
Next Divdend (Est)
(2024-04-29)
€0 Estimate 0.00 %
Dividend Stability
0.01 Very Bad
Dividend Score
2.13
Pay Frequency
Insufficient data to determine frequency
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
LAR.DE Ex Dividend Knight 2023-09-12 Quarterly 0 0.00%
UNP.DE Ex Dividend Knight 2023-08-30 Quarterly 0 0.00%
EBO.DE Ex Dividend Junior 2023-05-16 Annually 0 0.00%
NMM.DE Ex Dividend Knight 2023-09-06 Quarterly 0 0.00%
ADE.DE Ex Dividend Junior 2023-08-14 Annually 0 0.00%
ZEG.DE Ex Dividend Knight 2023-08-10 Semi-Annually 0 0.00%
GDX.DE Ex Dividend Knight 2023-10-05 Quarterly 0 0.00%
PPX.DE Ex Dividend Knight 2023-05-02 Semi-Annually 0 0.00%
BC8.DE Ex Dividend Knight 2023-05-26 Annually 0 0.00%
I93.F Ex Dividend Junior 2023-08-28 Quarterly 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1741.5006.539.79[0 - 0.5]
returnOnAssetsTTM0.05581.2008.149.77[0 - 0.3]
returnOnEquityTTM0.09301.500-0.0782-0.117[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM1.9900.8005.054.04[1 - 3]
quickRatioTTM1.4580.8006.134.90[0.8 - 2.5]
cashRatioTTM0.6191.5007.6710.00[0.2 - 2]
debtRatioTTM0.251-1.5005.82-8.74[0 - 0.6]
interestCoverageTTM8.281.0008.048.04[3 - 30]
operatingCashFlowPerShareTTM2.082.009.3110.00[0 - 30]
freeCashFlowPerShareTTM1.3402.009.3310.00[0 - 20]
debtEquityRatioTTM0.402-1.5008.39-10.00[0 - 2.5]
grossProfitMarginTTM0.6281.0002.872.87[0.2 - 0.8]
operatingProfitMarginTTM0.2251.0007.507.50[0.1 - 0.6]
cashFlowToDebtRatioTTM0.3001.0009.459.45[0.2 - 2]
assetTurnoverTTM0.3210.800-1.191-0.953[0.5 - 2]
Total Score10.15

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM26.971.0007.380[1 - 100]
returnOnEquityTTM0.09302.50-0.0503-0.117[0.1 - 1.5]
freeCashFlowPerShareTTM1.3402.009.5510.00[0 - 30]
dividendYielPercentageTTM6.251.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM2.082.009.3110.00[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.09551.500-2.700[0.5 - 2]
operatingCashFlowSalesRatioTTM0.2341.0006.660[0.1 - 0.5]
Total Score3.99

Qiagen NV

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。